LABS MediPharm Labs

Европейская фармацевтическая компания STADA вступает в эксклюзивное партнерство по медицинскому каннабису с MediPharm Labs

Европейская фармацевтическая компания STADA вступает в эксклюзивное партнерство по медицинскому каннабису с MediPharm Labs
EN
08/10/2020

Underlying

LABSMediPharm Labs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediPharm Labs

 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; C...

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that David Pidduck will be stepping down from his role as the Company's Chief Executive Officer, effective January 23rd, 2026. The Board of Directors (the "Board") has appointed Greg Hunter, the Company's Chief Financial Officer, as Interim Chief Executive Officer, wh...

January 19, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the signing of a definitive supply agreement with Remidose Aerosols Inc. (“Remidose”) for the shipment of GMP-certified medicinal cannabis products to Costa Rica. “MediPharm Labs’ proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannab...

January 13, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportuni...

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order  to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the "Order")....

December 19, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Ste...

MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Shelley Potts will be stepping down from the Company’s Board of Directors (the “Board”), effective December 31, 2025. The Company also announced that Michael Bumby will be rejoining the Board, effective January 1, 2026, bringing extensive experience in finance and gove...

December 11, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Completes First Shipment to France

MediPharm Labs Completes First Shipment to France TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the completion of the Company's first shipment to France. This milestone follows a production agreement with an international medicinal cannabis organization. This strategic collaboration strengthens MediPharm's position as a trusted supplier of pharmaceutical-grade cannabis products and demonstrat...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch